Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Therapeutic Area Revenue Growth at Constant Currencies by Year
Therapeutic Area Revenue Growth at Constant Currencies (% cc) (%)
Novartis Therapeutic Area Revenue Growth at Constant Currencies: 3.0% in FY2025, down 33.0 pts from a year earlier.
Latest, FY2025
3.0%
Period ended Dec 31, 2025
Change on a year earlier
-33.0 pts
36.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Total cardiovascular, renal and metabolic | 8 959 | 8 576 | 4 | 3”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Therapeutic Area Revenue Growth at Constant Currencies (% cc) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.0% | -33.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 36.0% | 0.0 pts | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 36.0% | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Cite this data
StockData. (2026). Novartis Therapeutic Area Revenue Growth at Constant Currencies (%), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ta-crm-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.